Market Closed - Nasdaq Stockholm 07:59:43 2024-03-28 am EDT 5-day change 1st Jan Change
1.99 SEK +6.42% Intraday chart for Dignitana AB +5.29% -8.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dignicap Delta Study Underway in Brindisi, Italy CI
Sweden's Dignitana to Raise SEK19 Million via Rights Issues, Secures SEK5 Million Bridge Loan MT
Dignitana AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dignitana AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Dignitana Receives Japanese Market Approval for Medical Device for Cancer Patients MT
Dignitana Announces DigniCap Delta Receives Market Approval in Japan CI
Dignitana Announces Preliminary Results of DigniCap Delta Study Demonstrates 79% Efficacy CI
Dignitana Signs Exclusive Distribution Deal with OncoMedical MT
Dignitana AB Signs OncoMedical AG for Distribution in Switzerland and Liechtenstein CI
Dignitana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Dignitana AB Appoints Nomination Committee CI
Dignitana Signs Sales & Marketing Deal With US-based InfuSystem; Shares Drop MT
Dignitana AB Announces Sales and Marketing Partnership with InfuSystem Holdings, Inc. to Provide Scalp Cooling Systems in the United States CI
Palmetto GBA Medicare Contractor Backs Dignitana's Scalp Cooling Solution for Cancer Patients MT
Dignitana AB Announces Palmetto GBA Approves First Local Coverage Determination for Scalp Cooling Therapy CI
Dignitana AB Long-Term Study Demonstrates Safety and Efficacy of Scalp Cooling to Reduce Chemo Hair Loss CI
Dignitana AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Dignitana Expands Oneservice Collaboration to Include DigniCap Delta MT
Dignitana AB Expands Customer Service Coverage in Europe with Oneservice Partnership CI
Dignitana to Deliver Improved Scalp Cooling Technology to Minimize Chemotherapy-induced Hair Loss in Mexico MT
Dignitana AB Expands Partnership with Celeritas to Improve Scalp Cooling Technology Available in Mexico CI
Dignitana AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Dignitana to Bring Scalp Cooling System to Hong Kong, Macao via Science International MT
Dignitana AB Enters Hong Kong Market with Distributor Science International Corporation CI
Dignitana AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart Dignitana AB
More charts
Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient's head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
  1. Stock
  2. Equities
  3. Stock Dignitana AB - Nasdaq Stockholm
  4. News Dignitana AB
  5. Dignitana CEO To Step Down in May; Successor Appointed